{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:41:18Z","timestamp":1793911278700,"version":"4.8.0"},"reference-count":141,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100015411","name":"Ara Parseghian Medical Research Fund","doi-asserted-by":"publisher","award":["20241991"],"award-info":[{"award-number":["20241991"]}],"id":[{"id":"10.13039\/100015411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Spinal Muscular Atrophy (SMA) is a neuromuscular disorder precipitated by mutations or deletions in the Survival Motor Neuron 1 (\n                    <jats:italic>SMN1<\/jats:italic>\n                    ) gene. Although the\n                    <jats:italic>SMN2<\/jats:italic>\n                    gene partially compensates for SMN1 functional deficiency, its expression is regulated by complex epigenetic and environmental factors. This review comprehensively elucidates the regulatory mechanisms through which epigenetic modifications-encompassing DNA methylation, histone modifications, and non-coding RNAs-modulate\n                    <jats:italic>SMN2<\/jats:italic>\n                    gene expression and impact SMA pathogenesis and progression. We also briefly discuss how these epigenetic mechanisms may interact with selected environmental factors in modifying disease outcomes. Emerging evidence suggests that these epigenetic factors and environmental exposures interact synergistically to influence disease trajectory and may account for the heterogeneity observed in SMA clinical manifestations. These insights have given rise to novel therapeutic strategies, including pharmacological interventions targeting epigenetic pathways and optimized management of environmental factors. Integrating multi-omics analyses holds promise for advancing personalized precision medicine approaches for SMA and potentially improving patient outcomes.\n                  <\/jats:p>","DOI":"10.1186\/s13023-025-03857-3","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T12:51:29Z","timestamp":1752151889000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Epigenetic regulation in spinal muscular atrophy: emerging areas and future directions"],"prefix":"10.1186","volume":"20","author":[{"given":"Haoran","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nannan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9306-3267","authenticated-orcid":false,"given":"Zhiqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"issue":"1","key":"3857_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S, Burglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene[J]. Cell. 1995;80(1):155\u201365.","journal-title":"Cell"},{"issue":"1","key":"3857_CR2","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","volume":"12","author":"IEC Verhaart","year":"2017","unstructured":"Verhaart IEC, Robertson A, Wilson IJ, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review[J]. Orphanet J Rare Dis. 2017;12(1):124.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3857_CR3","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-022-00380-8","volume":"8","author":"E Mercuri","year":"2022","unstructured":"Mercuri E, Sumner CJ, Muntoni F, et al. Spinal muscular atrophy[J]. Nat Rev Dis Primers. 2022;8(1):52.","journal-title":"Nat Rev Dis Primers"},{"issue":"8","key":"3857_CR4","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrn2670","volume":"10","author":"AHCE Burghes","year":"2009","unstructured":"Burghes AHCE, Beattie. Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick?[J]. Nat Rev Neurosci. 2009;10(8):597\u2013609.","journal-title":"Nat Rev Neurosci"},{"issue":"2","key":"3857_CR5","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ajhg.2023.01.001","volume":"110","author":"X Chen","year":"2023","unstructured":"Chen X, Harting J, Farrow E, et al. Comprehensive SMN1 and SMN2 profiling for spinal muscular atrophy analysis using long-read PacBio HiFi sequencing[J]. Am J Hum Genet. 2023;110(2):240\u201350.","journal-title":"Am J Hum Genet"},{"key":"3857_CR6","doi-asserted-by":"crossref","unstructured":"Butchbach MER. Genomic variability in the survival motor neuron genes (SMN1 and SMN2): implications for spinal muscular atrophy phenotype and therapeutics Development[J]. Int J Mol Sci, 2021, 22(15).","DOI":"10.3390\/ijms22157896"},{"issue":"6","key":"3857_CR7","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1002\/cpt.2247","volume":"110","author":"G Baranello","year":"2021","unstructured":"Baranello G, Gorni K, Daigl M, et al. Prognostic factors and Treatment-Effect modifiers in spinal muscular Atrophy[J]. Clin Pharmacol Ther. 2021;110(6):1435\u201354.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"3857_CR8","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1055\/s-0029-1237423","volume":"27","author":"C Dupont","year":"2009","unstructured":"Dupont C, Armant DR, Brenner CA. Epigenetics: definition, mechanisms and clinical perspective[J]. Semin Reprod Med. 2009;27(5):351\u20137.","journal-title":"Semin Reprod Med"},{"key":"3857_CR9","doi-asserted-by":"crossref","unstructured":"Chudakova D, Kuzenkova L, Fisenko A et al. In search of spinal muscular atrophy disease Modifiers[J]. Int J Mol Sci, 2024, 25(20).","DOI":"10.3390\/ijms252011210"},{"key":"3857_CR10","doi-asserted-by":"crossref","unstructured":"Du J, Wu Q, Bae EJ. Epigenetics of skeletal muscle Atrophy[J]. Int J Mol Sci, 2024, 25(15).","DOI":"10.3390\/ijms25158362"},{"issue":"1","key":"3857_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21541264.2018.1558677","volume":"10","author":"ER Hinkle","year":"2019","unstructured":"Hinkle ER, Wiedner HJ, Black AJ, et al. RNA processing in skeletal muscle biology and disease[J]. Transcription. 2019;10(1):1\u201320.","journal-title":"Transcription"},{"issue":"6","key":"3857_CR12","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1111\/j.1471-4159.2009.06084.x","volume":"109","author":"SA Lunke","year":"2009","unstructured":"Lunke SA, El-Osta. The emerging role of epigenetic modifications and chromatin remodeling in spinal muscular atrophy[J]. J Neurochem. 2009;109(6):1557\u201369.","journal-title":"J Neurochem"},{"issue":"8","key":"3857_CR13","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1080\/14728222.2020.1783241","volume":"24","author":"RN Singh","year":"2020","unstructured":"Singh RN, Seo J, Singh NN. RNA in spinal muscular atrophy: therapeutic implications of targeting[J]. Expert Opin Ther Targets. 2020;24(8):731\u201343.","journal-title":"Expert Opin Ther Targets"},{"issue":"1","key":"3857_CR14","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.neuron.2016.11.033","volume":"93","author":"C d\u2019Ydewalle","year":"2017","unstructured":"d\u2019Ydewalle C, Ramos DM, Pyles NJ, et al. The antisense transcript SMN-AS1 regulates SMN expression and is a novel therapeutic target for spinal muscular Atrophy[J]. Neuron. 2017;93(1):66\u201379.","journal-title":"Neuron"},{"issue":"2","key":"3857_CR15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3233\/JND-150081","volume":"2","author":"SR Renusch","year":"2015","unstructured":"Renusch SR, Harshman S, Pi H, et al. Spinal muscular atrophy biomarker measurements from blood samples in a clinical trial of valproic acid in ambulatory Adults[J]. J Neuromuscul Dis. 2015;2(2):119\u201330.","journal-title":"J Neuromuscul Dis"},{"issue":"2","key":"3857_CR16","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/jnc.14935","volume":"153","author":"V Pagliarini","year":"2020","unstructured":"Pagliarini V, Guerra M, Di Rosa V, et al. Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in spinal muscular atrophy cells[J]. J Neurochem. 2020;153(2):264\u201375.","journal-title":"J Neurochem"},{"issue":"3","key":"3857_CR17","doi-asserted-by":"publisher","first-page":"e0121964","DOI":"10.1371\/journal.pone.0121964","volume":"10","author":"GY Zheleznyakova","year":"2015","unstructured":"Zheleznyakova GY, Nilsson EK, Kiselev AV, et al. Methylation levels of SLC23A2 and NCOR2 genes correlate with spinal muscular atrophy severity[J]. PLoS ONE. 2015;10(3):e0121964.","journal-title":"PLoS ONE"},{"issue":"1","key":"3857_CR18","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1631\/jzus.B1500072","volume":"17","author":"YY Cao","year":"2016","unstructured":"Cao YY, Qu YJ, He SX, et al. Association between SMN2 methylation and disease severity in Chinese children with spinal muscular atrophy[J]. J Zhejiang Univ Sci B. 2016;17(1):76\u201382.","journal-title":"J Zhejiang Univ Sci B"},{"key":"3857_CR19","doi-asserted-by":"crossref","unstructured":"Martin LJ, Adams DA, Niedzwiecki MV et al. Aberrant DNA and RNA methylation occur in spinal cord and skeletal muscle of human SOD1 mouse models of ALS and in human ALS: targeting DNA methylation is Therapeutic[J]. Cells, 2022, 11(21).","DOI":"10.3390\/cells11213448"},{"issue":"1","key":"3857_CR20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1086\/498853","volume":"78","author":"L Cartegni","year":"2006","unstructured":"Cartegni L, Hastings ML, Calarco JA, et al. Determinants of exon 7 splicing in the spinal muscular atrophy genes, SMN1 and SMN2[J]. Am J Hum Genet. 2006;78(1):63\u201377.","journal-title":"Am J Hum Genet"},{"issue":"10","key":"3857_CR21","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1093\/hmg\/ddab350","volume":"31","author":"J Wang","year":"2022","unstructured":"Wang J, Bai J, OuYang S, et al. Antisense oligonucleotides targeting the SMN2 promoter region enhance SMN2 expression in spinal muscular atrophy cell lines and mouse model[J]. Hum Mol Genet. 2022;31(10):1635\u201350.","journal-title":"Hum Mol Genet"},{"issue":"9","key":"3857_CR22","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1073\/pnas.0700343104","volume":"104","author":"T Kashima","year":"2007","unstructured":"Kashima T, Rao N, Manley JL. An intronic element contributes to splicing repression in spinal muscular atrophy[J]. Proc Natl Acad Sci U S A. 2007;104(9):3426\u201331.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"3857_CR23","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/hmg\/ddx166","volume":"26","author":"X Wu","year":"2017","unstructured":"Wu X, Wang SH, Sun J, et al. A-44G transition in SMN2 intron 6 protects patients with spinal muscular atrophy[J]. Hum Mol Genet. 2017;26(14):2768\u201380.","journal-title":"Hum Mol Genet"},{"issue":"6","key":"3857_CR24","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1093\/hmg\/ddac260","volume":"32","author":"L Wang","year":"2023","unstructured":"Wang L, Ji Y, Chen Y, et al. A splicing silencer in SMN2 intron 6 is critical in spinal muscular atrophy[J]. Hum Mol Genet. 2023;32(6):971\u201383.","journal-title":"Hum Mol Genet"},{"issue":"12","key":"3857_CR25","doi-asserted-by":"publisher","first-page":"E2347","DOI":"10.1073\/pnas.1613181114","volume":"114","author":"M Jangi","year":"2017","unstructured":"Jangi M, Fleet C, Cullen P, et al. SMN deficiency in severe models of spinal muscular atrophy causes widespread intron retention and DNA damage[J]. Proc Natl Acad Sci U S A. 2017;114(12):E2347\u201356.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"48","key":"3857_CR26","doi-asserted-by":"publisher","first-page":"19348","DOI":"10.1073\/pnas.1319280110","volume":"110","author":"Z Zhang","year":"2013","unstructured":"Zhang Z, Pinto AM, Wan L, et al. Dysregulation of synaptogenesis genes antecedes motor neuron pathology in spinal muscular atrophy[J]. Proc Natl Acad Sci U S A. 2013;110(48):19348\u201353.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"3857_CR27","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.cell.2008.03.031","volume":"133","author":"Z Zhang","year":"2008","unstructured":"Zhang Z, Lotti F, Dittmar K, et al. SMN deficiency causes tissue-specific perturbations in the repertoire of SnRNAs and widespread defects in splicing[J]. Cell. 2008;133(4):585\u2013600.","journal-title":"Cell"},{"issue":"12","key":"3857_CR28","doi-asserted-by":"publisher","first-page":"5948","DOI":"10.1093\/nar\/gkad259","volume":"51","author":"EW Ottesen","year":"2023","unstructured":"Ottesen EW, Singh NN, Luo D, et al. Diverse targets of SMN2-directed splicing-modulating small molecule therapeutics for spinal muscular atrophy[J]. Nucleic Acids Res. 2023;51(12):5948\u201380.","journal-title":"Nucleic Acids Res"},{"key":"3857_CR29","first-page":"27","volume":"12","author":"KR Deguise Marc-Olivier","year":"2019","unstructured":"Deguise Marc-Olivier KR. Chapter 2 - Into the unknown: chromatin signaling in spinal muscular atrophy[J]. Chromatin Signal Neurol Disorders. 2019;12:27\u201352.","journal-title":"Chromatin Signal Neurol Disorders"},{"issue":"12","key":"3857_CR30","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1016\/j.cell.2022.04.031","volume":"185","author":"LE Marasco","year":"2022","unstructured":"Marasco LE, Dujardin G, Sousa-Luis R, et al. Counteracting chromatin effects of a splicing-correcting antisense oligonucleotide improves its therapeutic efficacy in spinal muscular atrophy[J]. Cell. 2022;185(12):2057\u201370. e2015.","journal-title":"Cell"},{"issue":"1","key":"3857_CR31","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1093\/brain\/awz373","volume":"143","author":"A Kannan","year":"2020","unstructured":"Kannan A, Jiang X, He L, et al. ZPR1 prevents R-loop accumulation, upregulates SMN2 expression and rescues spinal muscular atrophy[J]. Brain. 2020;143(1):69\u201393.","journal-title":"Brain"},{"issue":"2","key":"3857_CR32","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1093\/hmg\/ddn357","volume":"18","author":"J Hauke","year":"2009","unstructured":"Hauke J, Riessland M, Lunke S, et al. Survival motor neuron gene 2 Silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition[J]. Hum Mol Genet. 2009;18(2):304\u201317.","journal-title":"Hum Mol Genet"},{"key":"3857_CR33","unstructured":"Kordala A. Identifying epigenetic regulators of survival motor neuron protein to treat spinal muscular atrophy[J]. University of Oxford, 2022, PhD thesis."},{"key":"3857_CR34","doi-asserted-by":"publisher","first-page":"1092488","DOI":"10.3389\/fncel.2023.1092488","volume":"17","author":"GM Riboldi","year":"2023","unstructured":"Riboldi GM, Faravelli I, Rinchetti P, et al. SMN post-translational modifications in spinal muscular atrophy[J]. Front Cell Neurosci. 2023;17:1092488.","journal-title":"Front Cell Neurosci"},{"issue":"9","key":"3857_CR35","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00018-022-04522-9","volume":"79","author":"NT Detering","year":"2022","unstructured":"Detering NT, Schuning T, Hensel N, et al. The phospho-landscape of the survival of motoneuron protein (SMN) protein: relevance for spinal muscular atrophy (SMA)[J]. Cell Mol Life Sci. 2022;79(9):497.","journal-title":"Cell Mol Life Sci"},{"issue":"9","key":"3857_CR36","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/ejhg.2012.293","volume":"21","author":"GY Zheleznyakova","year":"2013","unstructured":"Zheleznyakova GY, Voisin S, Kiselev AV, et al. Genome-wide analysis shows association of epigenetic changes in regulators of Rab and Rho GTPases with spinal muscular atrophy severity[J]. Eur J Hum Genet. 2013;21(9):988\u201393.","journal-title":"Eur J Hum Genet"},{"key":"3857_CR37","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3103\/S0095452724060033","volume":"58","author":"YH Kerui Huang","year":"2024","unstructured":"Kerui Huang YH, Fang X. Dan peng. Elucidation of the gene regulatory network related to spinal muscular Atrophy[J]. Cytol Genet. 2024;58:615\u201326.","journal-title":"Cytol Genet"},{"issue":"4","key":"3857_CR38","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s13311-013-0209-2","volume":"10","author":"SA Lunke","year":"2013","unstructured":"Lunke SA, El-Osta. Applicability of histone deacetylase Inhibition for the treatment of spinal muscular atrophy[J]. Neurotherapeutics. 2013;10(4):677\u201387.","journal-title":"Neurotherapeutics"},{"issue":"3","key":"3857_CR39","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1172\/JCI29562","volume":"117","author":"AM Avila","year":"2007","unstructured":"Avila AM, Burnett BG, Taye AA, et al. Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy[J]. J Clin Invest. 2007;117(3):659\u201371.","journal-title":"J Clin Invest"},{"issue":"2","key":"3857_CR40","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1517\/13543784.17.2.169","volume":"17","author":"E Hahnen","year":"2008","unstructured":"Hahnen E, Hauke J, Trankle C, et al. Histone deacetylase inhibitors: possible implications for neurodegenerative disorders[J]. Expert Opin Investig Drugs. 2008;17(2):169\u201384.","journal-title":"Expert Opin Investig Drugs"},{"issue":"9","key":"3857_CR41","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/jhg.2016.61","volume":"61","author":"J Mohseni","year":"2016","unstructured":"Mohseni J, Al-Najjar BO, Wahab HA, et al. Transcript, methylation and molecular Docking analyses of the effects of HDAC inhibitors, SAHA and dacinostat, on SMN2 expression in fibroblasts of SMA patients[J]. J Hum Genet. 2016;61(9):823\u201330.","journal-title":"J Hum Genet"},{"key":"3857_CR42","doi-asserted-by":"crossref","unstructured":"Sibel Pinar Odabas EB, Yelgen G, Metin AS, Karakaya E, Gulden G, Sert B, Teymur T. Yasin Ay, Nulifer Neslihan Tiryaki, Hasret Araz, Ilayda Cavrar, Cihan Tastan. Exon7 Targeted CRISPR-Prime Editing Approaches for SMN2 Gene Editing in Spinal Muscular Atrophy (SMA) Disease Can Increase In Vitro SMN Expression[J]. bioRxiv, 2022: 484406.","DOI":"10.1101\/2022.03.21.484406"},{"issue":"Pt 16","key":"3857_CR43","first-page":"3664","volume":"126","author":"M Sabra","year":"2013","unstructured":"Sabra M, Texier P, Maalouf JE, et al. The Tudor protein survival motor neuron (SMN) is a chromatin-binding protein that interacts with methylated lysine 79 of histone H3[J]. J Cell Sci. 2013;126(Pt 16):3664\u201377.","journal-title":"J Cell Sci"},{"issue":"8","key":"3857_CR44","doi-asserted-by":"publisher","first-page":"E1509","DOI":"10.1073\/pnas.1616521114","volume":"114","author":"CJ Woo","year":"2017","unstructured":"Woo CJ, Maier VK, Davey R, et al. Gene activation of SMN by selective disruption of lncRNA-mediated recruitment of PRC2 for the treatment of spinal muscular atrophy[J]. Proc Natl Acad Sci U S A. 2017;114(8):E1509\u201318.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"3857_CR45","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/jcmm.13450","volume":"22","author":"F Magri","year":"2018","unstructured":"Magri F, Vanoli F, Corti S. MiRNA in spinal muscular atrophy pathogenesis and therapy[J]. J Cell Mol Med. 2018;22(2):755\u201367.","journal-title":"J Cell Mol Med"},{"key":"3857_CR46","doi-asserted-by":"crossref","unstructured":"Luo D, Singh NN, Singh RN. Internal introns promote backsplicing to generate circular RNAs from spinal muscular atrophy Gene[J]. Genes (Basel), 2022, 13(7).","DOI":"10.3390\/genes13071145"},{"issue":"9","key":"3857_CR47","doi-asserted-by":"publisher","first-page":"e1010392","DOI":"10.1371\/journal.pgen.1010392","volume":"18","author":"J Sun","year":"2022","unstructured":"Sun J, Qiu J, Yang Q, et al. Single-cell RNA sequencing reveals dysregulation of spinal cord cell types in a severe spinal muscular atrophy mouse model[J]. PLoS Genet. 2022;18(9):e1010392.","journal-title":"PLoS Genet"},{"key":"3857_CR48","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.nbd.2017.08.004","volume":"108","author":"O Tapia","year":"2017","unstructured":"Tapia O, Narcis JO, Riancho J, et al. Cellular bases of the RNA metabolism dysfunction in motor neurons of a murine model of spinal muscular atrophy: role of Cajal bodies and the nucleolus[J]. Neurobiol Dis. 2017;108:83\u201399.","journal-title":"Neurobiol Dis"},{"issue":"11","key":"3857_CR49","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1093\/hmg\/ddab365","volume":"31","author":"E Welby","year":"2022","unstructured":"Welby E, Rehborg RJ, Harmelink M, et al. Assessment of cerebral spinal fluid biomarkers and microRNA-mediated disease mechanisms in spinal muscular atrophy patient samples[J]. Hum Mol Genet. 2022;31(11):1830\u201343.","journal-title":"Hum Mol Genet"},{"issue":"7","key":"3857_CR50","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.nmd.2016.05.005","volume":"26","author":"GE Moore","year":"2016","unstructured":"Moore GE, Lindenmayer AW, McConchie GA, et al. Describing nutrition in spinal muscular atrophy: A systematic review[J]. Neuromuscul Disord. 2016;26(7):395\u2013404.","journal-title":"Neuromuscul Disord"},{"key":"3857_CR51","doi-asserted-by":"crossref","unstructured":"Li YJ, Chen TH, Wu YZ et al. Metabolic and nutritional issues associated with spinal muscular Atrophy[J]. Nutrients, 2020, 12(12).","DOI":"10.3390\/nu12123842"},{"key":"3857_CR52","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.pediatrneurol.2015.12.015","volume":"57","author":"NM Mehta","year":"2016","unstructured":"Mehta NM, Newman H, Tarrant S, et al. Nutritional status and nutrient intake challenges in children with spinal muscular Atrophy[J]. Pediatr Neurol. 2016;57:80\u20133.","journal-title":"Pediatr Neurol"},{"issue":"6","key":"3857_CR53","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.nmd.2018.03.009","volume":"28","author":"EE Martinez","year":"2018","unstructured":"Martinez EE, Quinn N, Arouchon K, et al. Comprehensive nutritional and metabolic assessment in patients with spinal muscular atrophy: opportunity for an individualized approach[J]. Neuromuscul Disord. 2018;28(6):512\u20139.","journal-title":"Neuromuscul Disord"},{"issue":"7","key":"3857_CR54","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1080\/1028415X.2020.1871212","volume":"25","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Chen J, Gong X, et al. Nutrition status survey of type 2 and 3 spinal muscular atrophy in Chinese population[J]. Nutr Neurosci. 2022;25(7):1488\u201394.","journal-title":"Nutr Neurosci"},{"issue":"8","key":"3857_CR55","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1002\/acn3.50855","volume":"6","author":"MO Deguise","year":"2019","unstructured":"Deguise MO, Baranello G, Mastella C, et al. Abnormal fatty acid metabolism is a core component of spinal muscular atrophy[J]. Ann Clin Transl Neurol. 2019;6(8):1519\u201332.","journal-title":"Ann Clin Transl Neurol"},{"key":"3857_CR56","doi-asserted-by":"crossref","unstructured":"Watson KS, Boukhloufi I, Bowerman M et al. The relationship between body composition, fatty acid metabolism and diet in spinal muscular Atrophy[J]. Brain Sci, 2021, 11(2).","DOI":"10.3390\/brainsci11020131"},{"issue":"10","key":"3857_CR57","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1097\/CM9.0000000000003049","volume":"137","author":"Y Feng","year":"2024","unstructured":"Feng Y, Wei J, Yao M, et al. Nutritional and lipid profile status of children with spinal muscular atrophy in china: A retrospective case-control study[J]. Chin Med J (Engl). 2024;137(10):1243\u20135.","journal-title":"Chin Med J (Engl)"},{"issue":"4","key":"3857_CR58","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/ncp.10940","volume":"38","author":"G O\u2019Connor","year":"2023","unstructured":"O\u2019Connor G, Edel L, Raquq S, et al. Open-labelled study to monitor the effect of an amino acid formula on symptom management in children with spinal muscular atrophy type I: the SMAAF pilot study[J]. Nutr Clin Pract. 2023;38(4):871\u201380.","journal-title":"Nutr Clin Pract"},{"key":"3857_CR59","doi-asserted-by":"crossref","unstructured":"Pinar E, Ayvaz BB, Akkus E et al. Exploring the influence of concurrent nutritional therapy on children with spinal muscular atrophy receiving Nusinersen Treatment[J]. Child (Basel), 2024, 11(8).","DOI":"10.3390\/children11080886"},{"issue":"11","key":"3857_CR60","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.nmd.2012.04.008","volume":"22","author":"KE Poruk","year":"2012","unstructured":"Poruk KE, Davis RH, Smart AL, et al. Observational study of caloric and nutrient intake, bone density, and body composition in infants and children with spinal muscular atrophy type I[J]. Neuromuscul Disord. 2012;22(11):966\u201373.","journal-title":"Neuromuscul Disord"},{"key":"3857_CR61","doi-asserted-by":"crossref","unstructured":"Aziz T, Khan AA, Tzora A et al. Dietary implications of the bidirectional relationship between the gut microflora and inflammatory diseases with special emphasis on irritable bowel disease: current and future Perspective[J]. Nutrients, 2023, 15(13).","DOI":"10.3390\/nu15132956"},{"key":"3857_CR62","doi-asserted-by":"publisher","first-page":"175628642110356","DOI":"10.1177\/17562864211035657","volume":"14","author":"A Totzeck","year":"2021","unstructured":"Totzeck A, Ramakrishnan E, Schlag M, et al. Gut bacterial microbiota in patients with myasthenia gravis: results from the MYBIOM study[J]. Ther Adv Neurol Disord. 2021;14:17562864211035657.","journal-title":"Ther Adv Neurol Disord"},{"issue":"5","key":"3857_CR63","first-page":"100479","volume":"4","author":"S Chen","year":"2023","unstructured":"Chen S, Zhang P, Duan H, et al. Gut microbiota in muscular atrophy development, progression, and treatment: new therapeutic targets and opportunities[J]. Innov (Camb). 2023;4(5):100479.","journal-title":"Innov (Camb)"},{"issue":"4","key":"3857_CR64","doi-asserted-by":"publisher","first-page":"e14718","DOI":"10.1111\/cns.14718","volume":"30","author":"M Lu","year":"2024","unstructured":"Lu M, Wang X, Sun N, et al. Metabolomics of cerebrospinal fluid reveals candidate diagnostic biomarkers to distinguish between spinal muscular atrophy type II and type III[J]. CNS Neurosci Ther. 2024;30(4):e14718.","journal-title":"CNS Neurosci Ther"},{"issue":"3","key":"3857_CR65","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s40120-023-00477-6","volume":"12","author":"Y Feng","year":"2023","unstructured":"Feng Y, Cui Y, Jin J, et al. The alterations of gut Microbiome and lipid metabolism in patients with spinal muscular Atrophy[J]. Neurol Ther. 2023;12(3):961\u201376.","journal-title":"Neurol Ther"},{"issue":"7770","key":"3857_CR66","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41586-019-1443-5","volume":"572","author":"E Blacher","year":"2019","unstructured":"Blacher E, Bashiardes S, Shapiro H, et al. Potential roles of gut Microbiome and metabolites in modulating ALS in mice[J]. Nature. 2019;572(7770):474\u201380.","journal-title":"Nature"},{"issue":"7","key":"3857_CR67","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/j.cell.2018.04.027","volume":"173","author":"CA Olson","year":"2018","unstructured":"Olson CA, Vuong HE, Yano JM, et al. The gut microbiota mediates the Anti-Seizure effects of the ketogenic Diet[J]. Cell. 2018;173(7):1728\u2013e17411713.","journal-title":"Cell"},{"issue":"1","key":"3857_CR68","doi-asserted-by":"publisher","first-page":"2363880","DOI":"10.1080\/19490976.2024.2363880","volume":"16","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Xia Y, Sun J. Probiotics and microbial metabolites maintain barrier and neuromuscular functions and clean protein aggregation to delay disease progression in TDP43 mutation mice[J]. Gut Microbes. 2024;16(1):2363880.","journal-title":"Gut Microbes"},{"issue":"1","key":"3857_CR69","doi-asserted-by":"publisher","first-page":"2363015","DOI":"10.1080\/19490976.2024.2363015","volume":"16","author":"M Cescon","year":"2024","unstructured":"Cescon M, Gambarotta G, Calabro S, et al. Gut microbiota depletion delays somatic peripheral nerve development and impairs neuromuscular junction maturation[J]. Gut Microbes. 2024;16(1):2363015.","journal-title":"Gut Microbes"},{"key":"3857_CR70","unstructured":"CADILE F. Molecular determinants of diaphragm muscle impairment in a mouse model of spinal muscular atrophy and a possible nutraceutical intervention[J]. Tesi di dottorato; 2024."},{"key":"3857_CR71","doi-asserted-by":"publisher","first-page":"101739","DOI":"10.1016\/j.arr.2022.101739","volume":"81","author":"T Zhang","year":"2022","unstructured":"Zhang T, Cheng JK, Hu YM. Gut microbiota as a promising therapeutic target for age-related sarcopenia[J]. Ageing Res Rev. 2022;81:101739.","journal-title":"Ageing Res Rev"},{"issue":"11","key":"3857_CR72","doi-asserted-by":"publisher","first-page":"8779","DOI":"10.1002\/fsn3.4550","volume":"12","author":"W Li","year":"2024","unstructured":"Li W, Sheng RW, Cao MM, et al. Exploring the relationship between gut microbiota and sarcopenia based on gut-Muscle Axis[J]. Food Sci Nutr. 2024;12(11):8779\u201392.","journal-title":"Food Sci Nutr"},{"key":"3857_CR73","doi-asserted-by":"crossref","unstructured":"Calabro S, Kankowski S, Cescon M et al. Impact of gut microbiota on the peripheral nervous system in physiological, regenerative and pathological Conditions[J]. Int J Mol Sci, 2023, 24(9).","DOI":"10.3390\/ijms24098061"},{"key":"3857_CR74","doi-asserted-by":"crossref","unstructured":"Meneri M, Abati E, Gagliardi D et al. Identification of novel biomarkers of spinal muscular atrophy and therapeutic response by proteomic and metabolomic profiling of human biological fluid Samples[J]. Biomedicines, 2023, 11(5).","DOI":"10.3390\/biomedicines11051254"},{"issue":"6","key":"3857_CR75","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.ejpn.2018.08.009","volume":"22","author":"EFD Tizzano","year":"2018","unstructured":"Tizzano EFD, Zafeiriou. Prenatal aspects in spinal muscular atrophy: from early detection to early presymptomatic intervention[J]. Eur J Paediatr Neurol. 2018;22(6):944\u201350.","journal-title":"Eur J Paediatr Neurol"},{"key":"3857_CR76","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2147\/TCRM.S172291","volume":"15","author":"TL Dangouloff","year":"2019","unstructured":"Dangouloff TL, Servais. Clinical evidence supporting early treatment of patients with spinal muscular atrophy: current Perspectives[J]. Ther Clin Risk Manag. 2019;15:1153\u201361.","journal-title":"Ther Clin Risk Manag"},{"key":"3857_CR77","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-022-00380-8","volume":"8","author":"E Mercuri","year":"2022","unstructured":"Mercuri E, Sumner CJ, Muntoni F. Spinal muscular atrophy[J]. Nat Rev Dis Primers. 2022;8:52.","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"3857_CR78","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1080\/13543784.2021.1904889","volume":"30","author":"L Servais","year":"2021","unstructured":"Servais L, Baranello G, Scoto M, et al. Therapeutic interventions for spinal muscular atrophy: preclinical and early clinical development opportunities[J]. Expert Opin Investig Drugs. 2021;30(5):519\u201327.","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"3857_CR79","doi-asserted-by":"publisher","first-page":"179","DOI":"10.31083\/j.fbl2706179","volume":"27","author":"A Mirea","year":"2022","unstructured":"Mirea A, Leanca MC, Onose G, et al. Physical therapy and Nusinersen impact on spinal muscular atrophy rehabilitative Outcome[J]. Front Biosci (Landmark Ed). 2022;27(6):179.","journal-title":"Front Biosci (Landmark Ed)"},{"key":"3857_CR80","doi-asserted-by":"crossref","unstructured":"Francesca R, No. SMA can hold: Nursing care for children with spinal muscular atrophy. Descriptive analysis of two case studies[J]. Revista Cient\u00edfica de la Sociedad de Enfermer\u00eda Neurol\u00f3gica (English ed.), 2024, 60: 100144.","DOI":"10.1016\/j.sedeng.2024.100144"},{"key":"3857_CR81","doi-asserted-by":"publisher","first-page":"55","DOI":"10.5734\/JGM.2020.17.2.55","volume":"17","author":"YY Dae-Hyun","year":"2020","unstructured":"Dae-Hyun YY. Rehabilitation of spinal muscular atrophy: current consensus and future direction[J]. J Genet Med. 2020;17:55\u201361.","journal-title":"J Genet Med"},{"issue":"4","key":"3857_CR82","doi-asserted-by":"publisher","first-page":"e0249279","DOI":"10.1371\/journal.pone.0249279","volume":"16","author":"JF Timmerberg","year":"2021","unstructured":"Timmerberg JF, Krosschell KJ, Dunaway Young S, et al. Essential competencies for physical therapist managing individuals with spinal muscular atrophy: A Delphi study[J]. PLoS ONE. 2021;16(4):e0249279.","journal-title":"PLoS ONE"},{"issue":"5","key":"3857_CR83","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.nmd.2021.02.011","volume":"31","author":"J Trenkle","year":"2021","unstructured":"Trenkle J, Brugman J, Peterson A, et al. Filling the gaps in knowledge translation: physical therapy recommendations for individuals with spinal muscular atrophy compared to standard of care guidelines[J]. Neuromuscul Disord. 2021;31(5):397\u2013408.","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"3857_CR84","first-page":"247","volume":"17","author":"F Ahmed","year":"2024","unstructured":"Ahmed F, Islam A, Akter S, et al. Multidisciplinary physical rehabilitation program of individuals with spinal muscular atrophy in an inclusive school setting[J]. J Pediatr Rehabil Med. 2024;17(2):247\u201352.","journal-title":"J Pediatr Rehabil Med"},{"issue":"11","key":"3857_CR85","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1111\/jan.13042","volume":"72","author":"HM Ho","year":"2016","unstructured":"Ho HM, Tseng YH, Hsin YM, et al. Living with illness and self-transcendence: the lived experience of patients with spinal muscular atrophy[J]. J Adv Nurs. 2016;72(11):2695\u2013705.","journal-title":"J Adv Nurs"},{"key":"3857_CR86","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s12883-015-0473-3","volume":"15","author":"Y Qian","year":"2015","unstructured":"Qian Y, McGraw S, Henne J, et al. Understanding the experiences and needs of individuals with spinal muscular atrophy and their parents: a qualitative study[J]. BMC Neurol. 2015;15:217.","journal-title":"BMC Neurol"},{"issue":"1","key":"3857_CR87","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s13023-020-01477-7","volume":"15","author":"P Kiefer","year":"2020","unstructured":"Kiefer P, Kirschner J, Pechmann A, et al. Experiences of caregivers of children with spinal muscular atrophy participating in the expanded access program for nusinersen: a longitudinal qualitative study[J]. Orphanet J Rare Dis. 2020;15(1):194.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"3857_CR88","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1177\/0883073819900463","volume":"35","author":"MS Weaver","year":"2020","unstructured":"Weaver MS, Hanna R, Hetzel S, et al. A prospective, crossover survey study of Child- and Proxy-Reported quality of life according to spinal muscular atrophy type and medical Interventions[J]. J Child Neurol. 2020;35(5):322\u201330.","journal-title":"J Child Neurol"},{"key":"3857_CR89","doi-asserted-by":"crossref","unstructured":"Pena-Longobardo LM, Aranda-Reneo I, Oliva-Moreno J et al. The economic impact and Health-Related quality of life of spinal muscular atrophy. An analysis across Europe[J]. Int J Environ Res Public Health, 2020, 17(16).","DOI":"10.3390\/ijerph17165640"},{"issue":"6","key":"3857_CR90","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/nrn2639","volume":"10","author":"SJ Lupien","year":"2009","unstructured":"Lupien SJ, McEwen BS, Gunnar MR, et al. Effects of stress throughout the lifespan on the brain, behaviour and cognition[J]. Nat Rev Neurosci. 2009;10(6):434\u201345.","journal-title":"Nat Rev Neurosci"},{"issue":"5","key":"3857_CR91","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/dmcn.14798","volume":"63","author":"R Masson","year":"2021","unstructured":"Masson R, Brusa C, Scoto M, et al. Brain, cognition, and Language development in spinal muscular atrophy type 1: a scoping review[J]. Dev Med Child Neurol. 2021;63(5):527\u201336.","journal-title":"Dev Med Child Neurol"},{"key":"3857_CR92","doi-asserted-by":"publisher","first-page":"134625","DOI":"10.1016\/j.chemosphere.2022.134625","volume":"301","author":"B Vellingiri","year":"2022","unstructured":"Vellingiri B, Suriyanarayanan A, Selvaraj P, et al. Role of heavy metals (copper (Cu), arsenic (As), cadmium (Cd), iron (Fe) and lithium (Li)) induced neurotoxicity[J]. Chemosphere. 2022;301:134625.","journal-title":"Chemosphere"},{"key":"3857_CR93","unstructured":"Qi Long YF, Yu Y, Chen F, Ma M, Mao S. Association between serum copper concentrations and body composition in children with spinal muscular atrophy: a cross-sectional study[J]. Asia Pac J Clin Nutr, 2024: 1\u201314."},{"key":"3857_CR94","doi-asserted-by":"crossref","first-page":"091","DOI":"10.1002\/cjp2.121","volume":"5","author":"SDAI Taruna","year":"2019","unstructured":"Taruna SDAI. Atypical levels of heavy metals, creatinine, haptoglobin, and ferritin found in amyotrophic lateral sclerosis outpatients vs. Healthy controls: possible utility as a diagnostic Biomarker[J]. Int J Pathol Clin Res. 2019;5:091.","journal-title":"Int J Pathol Clin Res"},{"issue":"1\u20132","key":"3857_CR95","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jns.2015.10.023","volume":"359","author":"B Bocca","year":"2015","unstructured":"Bocca B, Forte G, Oggiano R, et al. Level of neurotoxic metals in amyotrophic lateral sclerosis: A population-based case-control study[J]. J Neurol Sci. 2015;359(1\u20132):11\u20137.","journal-title":"J Neurol Sci"},{"issue":"8","key":"3857_CR96","first-page":"19","volume":"18","author":"AMGV Sateesh Kumar Talabhaktula","year":"2019","unstructured":"Sateesh Kumar Talabhaktula AMGV, Butchi Raju Garuda G, Seepana, Aruna Kumari U. Clinical and electrophysiological profile of amyotrophic lateral sclerosis and study of plasma levels of neurotoxic metals as a significant risk factor in development of amyotrophic lateral sclerosis[J]. IOSR J Dent Med Sci. 2019;18(8):19\u201333.","journal-title":"IOSR J Dent Med Sci"},{"key":"3857_CR97","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.envint.2018.12.026","volume":"123","author":"C Donat-Vargas","year":"2019","unstructured":"Donat-Vargas C, Bergdahl IA, Tornevi A, et al. Perfluoroalkyl substances and risk of type II diabetes: A prospective nested case-control study[J]. Environ Int. 2019;123:390\u20138.","journal-title":"Environ Int"},{"issue":"10267","key":"3857_CR98","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1016\/S0140-6736(20)32340-0","volume":"396","author":"A Cieza","year":"2021","unstructured":"Cieza A, Causey K, Kamenov K, et al. Global estimates of the need for rehabilitation based on the global burden of disease study 2019: a systematic analysis for the global burden of disease study 2019[J]. Lancet. 2021;396(10267):2006\u201317.","journal-title":"Lancet"},{"issue":"6","key":"3857_CR99","doi-asserted-by":"publisher","first-page":"3428","DOI":"10.1021\/acs.est.9b07295","volume":"54","author":"WP Qin","year":"2020","unstructured":"Qin WP, Cao LY, Li CH, et al. Perfluoroalkyl substances stimulate insulin secretion by islet beta cells via G Protein-Coupled receptor 40[J]. Environ Sci Technol. 2020;54(6):3428\u201336.","journal-title":"Environ Sci Technol"},{"issue":"5\u20137","key":"3857_CR100","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1080\/10937404.2011.578557","volume":"14","author":"YM Masuo","year":"2011","unstructured":"Masuo YM, Ishido. Neurotoxicity of endocrine disruptors: possible involvement in brain development and neurodegeneration[J]. J Toxicol Environ Health B Crit Rev. 2011;14(5\u20137):346\u201369.","journal-title":"J Toxicol Environ Health B Crit Rev"},{"issue":"1","key":"3857_CR101","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/j.1365-2826.2011.02229.x","volume":"24","author":"CA Frye","year":"2012","unstructured":"Frye CA, Bo E, Calamandrei G, et al. Endocrine disrupters: a review of some sources, effects, and mechanisms of actions on behaviour and neuroendocrine systems[J]. J Neuroendocrinol. 2012;24(1):144\u201359.","journal-title":"J Neuroendocrinol"},{"issue":"1","key":"3857_CR102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00204-023-03614-0","volume":"98","author":"HEE Costa","year":"2024","unstructured":"Costa HEE, Cairrao. Effect of bisphenol A on the neurological system: a review update[J]. Arch Toxicol. 2024;98(1):1\u201373.","journal-title":"Arch Toxicol"},{"issue":"38","key":"3857_CR103","first-page":"16774","volume":"58","author":"KM Rios-Bonilla","year":"2024","unstructured":"Rios-Bonilla KM, Aga DS, Lee J, et al. Neurotoxic effects of mixtures of perfluoroalkyl substances (PFAS) at environmental and human blood Concentrations[J]. Environ Sci Technol. 2024;58(38):16774\u201384.","journal-title":"Environ Sci Technol"},{"issue":"10","key":"3857_CR104","doi-asserted-by":"publisher","first-page":"105001","DOI":"10.1289\/EHP9285","volume":"129","author":"HB Patisaul","year":"2021","unstructured":"Patisaul HB, Behl M, Birnbaum LS, et al. Beyond cholinesterase inhibition: developmental neurotoxicity of organophosphate ester flame retardants and Plasticizers[J]. Environ Health Perspect. 2021;129(10):105001.","journal-title":"Environ Health Perspect"},{"key":"3857_CR105","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.neuro.2020.12.009","volume":"83","author":"V Naffaa","year":"2021","unstructured":"Naffaa V, Laprevote O, Schang AL. Effects of endocrine disrupting chemicals on Myelin development and diseases[J]. Neurotoxicology. 2021;83:51\u201368.","journal-title":"Neurotoxicology"},{"key":"3857_CR106","doi-asserted-by":"publisher","first-page":"111829","DOI":"10.1016\/j.envres.2021.111829","volume":"203","author":"GL Raja","year":"2022","unstructured":"Raja GL, Subhashree KD, Kantayya KE. In utero exposure to endocrine disruptors and developmental neurotoxicity: implications for behavioural and neurological disorders in adult life[J]. Environ Res. 2022;203:111829.","journal-title":"Environ Res"},{"key":"3857_CR107","doi-asserted-by":"publisher","first-page":"107523","DOI":"10.1016\/j.pharmthera.2020.107523","volume":"210","author":"LG Costa","year":"2020","unstructured":"Costa LG, Cole TB, Dao K, et al. Effects of air pollution on the nervous system and its possible role in neurodevelopmental and neurodegenerative disorders[J]. Pharmacol Ther. 2020;210:107523.","journal-title":"Pharmacol Ther"},{"issue":"Pt A","key":"3857_CR108","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.envpol.2018.07.031","volume":"242","author":"Q Zhang","year":"2018","unstructured":"Zhang Q, Li Q, Ma J, et al. PM2.5 impairs neurobehavior by oxidative stress and Myelin sheaths injury of brain in the rat[J]. Environ Pollut. 2018;242(Pt A):994\u20131001.","journal-title":"Environ Pollut"},{"issue":"3","key":"3857_CR109","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3233\/JAD-190015","volume":"69","author":"EM Thomson","year":"2019","unstructured":"Thomson EM, Air Pollution. Stress, and allostatic load: linking systemic and central nervous system Impacts[J]. J Alzheimers Dis. 2019;69(3):597\u2013614.","journal-title":"J Alzheimers Dis"},{"key":"3857_CR110","doi-asserted-by":"publisher","first-page":"113972","DOI":"10.1016\/j.ecoenv.2022.113972","volume":"243","author":"B Vellingiri","year":"2022","unstructured":"Vellingiri B, Chandrasekhar M, Sri Sabari S, et al. Neurotoxicity of pesticides - A link to neurodegeneration[J]. Ecotoxicol Environ Saf. 2022;243:113972.","journal-title":"Ecotoxicol Environ Saf"},{"issue":"3","key":"3857_CR111","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s00401-019-02033-9","volume":"138","author":"JR Richardson","year":"2019","unstructured":"Richardson JR, Fitsanakis V, Westerink RHS, et al. Neurotoxicity of pesticides[J]. Acta Neuropathol. 2019;138(3):343\u201362.","journal-title":"Acta Neuropathol"},{"key":"3857_CR112","doi-asserted-by":"publisher","first-page":"114494","DOI":"10.1016\/j.expneurol.2023.114494","volume":"368","author":"NE Scholpa","year":"2023","unstructured":"Scholpa NE. Role of DNA methylation during recovery from spinal cord injury with and without beta(2)-adrenergic receptor agonism[J]. Exp Neurol. 2023;368:114494.","journal-title":"Exp Neurol"},{"issue":"3","key":"3857_CR113","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1080\/15513815.2018.1520374","volume":"38","author":"S Bozorg Qomi","year":"2019","unstructured":"Bozorg Qomi S, Asghari A, Salmaninejad A, et al. Spinal muscular atrophy and common therapeutic Advances[J]. Fetal Pediatr Pathol. 2019;38(3):226\u201338.","journal-title":"Fetal Pediatr Pathol"},{"issue":"6","key":"3857_CR114","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1111\/acel.12387","volume":"14","author":"ME Walsh","year":"2015","unstructured":"Walsh ME, Bhattacharya A, Sataranatarajan K, et al. The histone deacetylase inhibitor butyrate improves metabolism and reduces muscle atrophy during aging[J]. Aging Cell. 2015;14(6):957\u201370.","journal-title":"Aging Cell"},{"issue":"4","key":"3857_CR115","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1152\/japplphysiol.01031.2014","volume":"119","author":"S Dupre-Aucouturier","year":"2015","unstructured":"Dupre-Aucouturier S, Castells J, Freyssenet D, et al. Trichostatin A, a histone deacetylase inhibitor, modulates unloaded-induced skeletal muscle atrophy[J]. J Appl Physiol (1985). 2015;119(4):342\u201351.","journal-title":"J Appl Physiol (1985)"},{"issue":"22","key":"3857_CR116","doi-asserted-by":"publisher","first-page":"10067","DOI":"10.1021\/acs.jmedchem.6b00670","volume":"59","author":"AN Calder","year":"2016","unstructured":"Calder AN, Androphy EJ, Hodgetts KJ. Small molecules in development for the treatment of spinal muscular Atrophy[J]. J Med Chem. 2016;59(22):10067\u201383.","journal-title":"J Med Chem"},{"issue":"15","key":"3857_CR117","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1016\/j.bmcl.2017.06.027","volume":"27","author":"JI Lai","year":"2017","unstructured":"Lai JI, Leman LJ, Ku S, et al. Cyclic tetrapeptide HDAC inhibitors as potential therapeutics for spinal muscular atrophy: screening with iPSC-derived neuronal cells[J]. Bioorg Med Chem Lett. 2017;27(15):3289\u201393.","journal-title":"Bioorg Med Chem Lett"},{"key":"3857_CR118","doi-asserted-by":"publisher","first-page":"117485","DOI":"10.1016\/j.jns.2021.117485","volume":"427","author":"G Gandhi","year":"2021","unstructured":"Gandhi G, Abdullah S, Foead AI, et al. The potential role of MiRNA therapies in spinal muscle atrophy[J]. J Neurol Sci. 2021;427:117485.","journal-title":"J Neurol Sci"},{"key":"3857_CR119","doi-asserted-by":"publisher","first-page":"175628642097995","DOI":"10.1177\/1756286420979954","volume":"13","author":"TH Chen","year":"2020","unstructured":"Chen TH. Circulating MicroRNAs as potential biomarkers and therapeutic targets in spinal muscular atrophy[J]. Ther Adv Neurol Disord. 2020;13:1756286420979954.","journal-title":"Ther Adv Neurol Disord"},{"key":"3857_CR120","doi-asserted-by":"crossref","unstructured":"D\u2019Silva AM, Kariyawasam D, Venkat P et al. Identification of novel CSF-Derived MiRNAs in treated paediatric onset spinal muscular atrophy: an exploratory Study[J]. Pharmaceutics, 2023, 15(1).","DOI":"10.3390\/pharmaceutics15010170"},{"key":"3857_CR121","doi-asserted-by":"crossref","unstructured":"Jung W, Juang U, Gwon S et al. MicroRNA\u2013mediated regulation of muscular atrophy: exploring molecular pathways and therapeutics (Review)[J]. Mol Med Rep, 2024, 29(6).","DOI":"10.3892\/mmr.2024.13222"},{"issue":"7","key":"3857_CR122","doi-asserted-by":"publisher","first-page":"e331","DOI":"10.1038\/mtna.2016.47","volume":"5","author":"F Catapano","year":"2016","unstructured":"Catapano F, Zaharieva I, Scoto M, et al. Altered levels of MicroRNA-9, -206, and\u2013\u2009132 in spinal muscular atrophy and their response to antisense oligonucleotide Therapy[J]. Mol Ther Nucleic Acids. 2016;5(7):e331.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"11","key":"3857_CR123","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/S1474-4422(09)70262-5","volume":"8","author":"RG Urdinguio","year":"2009","unstructured":"Urdinguio RG, Sanchez-Mut JV, Esteller M. Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies[J]. Lancet Neurol. 2009;8(11):1056\u201372.","journal-title":"Lancet Neurol"},{"issue":"1","key":"3857_CR124","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13578-023-00953-4","volume":"13","author":"D Jiang","year":"2023","unstructured":"Jiang D, Li T, Guo C, et al. Small molecule modulators of chromatin remodeling: from neurodevelopment to neurodegeneration[J]. Cell Biosci. 2023;13(1):10.","journal-title":"Cell Biosci"},{"issue":"11","key":"3857_CR125","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1093\/stcltm\/szac068","volume":"11","author":"JMA Saber","year":"2022","unstructured":"Saber JMA, Rudnicki. Carm1 and the epigenetic control of stem cell Function[J]. Stem Cells Transl Med. 2022;11(11):1143\u201350.","journal-title":"Stem Cells Transl Med"},{"issue":"9","key":"3857_CR126","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1093\/hmg\/ddab333","volume":"31","author":"A Ravel-Chapuis","year":"2022","unstructured":"Ravel-Chapuis A, Haghandish A, Daneshvar N, et al. A novel CARM1-HuR axis involved in muscle differentiation and plasticity misregulated in spinal muscular atrophy[J]. Hum Mol Genet. 2022;31(9):1453\u201370.","journal-title":"Hum Mol Genet"},{"issue":"2","key":"3857_CR127","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1093\/nar\/gkz1117","volume":"48","author":"V Pagliarini","year":"2020","unstructured":"Pagliarini V, Jolly A, Bielli P, et al. Sam68 binds Alu-rich introns in SMN and promotes pre-mRNA circularization[J]. Nucleic Acids Res. 2020;48(2):633\u201345.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"3857_CR128","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/jcsm.12542","volume":"11","author":"H Zhou","year":"2020","unstructured":"Zhou H, Meng J, Malerba A, et al. Myostatin Inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy[J]. J Cachexia Sarcopenia Muscle. 2020;11(3):768\u201382.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"7","key":"3857_CR129","doi-asserted-by":"publisher","first-page":"100346","DOI":"10.1016\/j.xcrm.2021.100346","volume":"2","author":"H Chaytow","year":"2021","unstructured":"Chaytow H, Faller KME, Huang YT, et al. Spinal muscular atrophy: from approved therapies to future therapeutic targets for personalized medicine[J]. Cell Rep Med. 2021;2(7):100346.","journal-title":"Cell Rep Med"},{"issue":"2","key":"3857_CR130","doi-asserted-by":"publisher","first-page":"151326","DOI":"10.1016\/j.ejcb.2023.151326","volume":"102","author":"ZT Nakevska","year":"2023","unstructured":"Nakevska ZT, Yokota. Challenges and future perspective of antisense therapy for spinal muscular atrophy: A review[J]. Eur J Cell Biol. 2023;102(2):151326.","journal-title":"Eur J Cell Biol"},{"issue":"1","key":"3857_CR131","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41467-022-35574-x","volume":"14","author":"ES Liau","year":"2023","unstructured":"Liau ES, Jin S, Chen YC, et al. Single-cell transcriptomic analysis reveals diversity within mammalian spinal motor neurons[J]. Nat Commun. 2023;14(1):46.","journal-title":"Nat Commun"},{"issue":"1","key":"3857_CR132","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10571-024-01499-w","volume":"44","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Li T, Wang G, et al. Advancements in Single-Cell RNA sequencing and Spatial transcriptomics for central nervous system Disease[J]. Cell Mol Neurobiol. 2024;44(1):65.","journal-title":"Cell Mol Neurobiol"},{"issue":"5","key":"3857_CR133","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/s41593-023-01311-w","volume":"26","author":"J Andersen","year":"2023","unstructured":"Andersen J, Thom N, Shadrach JL, et al. Single-cell transcriptomic landscape of the developing human spinal cord[J]. Nat Neurosci. 2023;26(5):902\u201314.","journal-title":"Nat Neurosci"},{"issue":"4","key":"3857_CR134","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s12031-024-02251-1","volume":"74","author":"M Liguori","year":"2024","unstructured":"Liguori M, Bianco A, Introna A, et al. An early transcriptomic investigation in adult patients with spinal muscular atrophy under treatment with Nusinersen[J]. J Mol Neurosci. 2024;74(4):89.","journal-title":"J Mol Neurosci"},{"issue":"1","key":"3857_CR135","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1093\/ije\/dyr154","volume":"41","author":"L Hou","year":"2012","unstructured":"Hou L, Zhang X, Wang D, et al. Environmental chemical exposures and human epigenetics[J]. Int J Epidemiol. 2012;41(1):79\u2013105.","journal-title":"Int J Epidemiol"},{"issue":"20","key":"3857_CR136","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1212\/WNL.0b013e3182749f28","volume":"79","author":"PC Lee","year":"2012","unstructured":"Lee PC, Bordelon Y, Bronstein J, et al. Traumatic brain injury, Paraquat exposure, and their relationship to Parkinson disease[J]. Neurology. 2012;79(20):2061\u20136.","journal-title":"Neurology"},{"issue":"1","key":"3857_CR137","doi-asserted-by":"publisher","first-page":"e1022","DOI":"10.1038\/tp.2016.280","volume":"7","author":"M Cacciottolo","year":"2017","unstructured":"Cacciottolo M, Wang X, Driscoll I, et al. Particulate air pollutants, APOE alleles and their contributions to cognitive impairment in older women and to amyloidogenesis in experimental models[J]. Transl Psychiatry. 2017;7(1):e1022.","journal-title":"Transl Psychiatry"},{"issue":"1","key":"3857_CR138","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1177\/0141076813511451","volume":"107","author":"D Baumer","year":"2014","unstructured":"Baumer D, Talbot K, Turner MR. Advances in motor neurone disease[J]. J R Soc Med. 2014;107(1):14\u201321.","journal-title":"J R Soc Med"},{"issue":"9","key":"3857_CR139","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1093\/brain\/awad075","volume":"146","author":"A Catanese","year":"2023","unstructured":"Catanese A, Rajkumar S, Sommer D, et al. Multiomics and machine-learning identify novel transcriptional and mutational signatures in amyotrophic lateral sclerosis[J]. Brain. 2023;146(9):3770\u201382.","journal-title":"Brain"},{"issue":"1","key":"3857_CR140","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nbt.3049","volume":"33","author":"Y Maury","year":"2015","unstructured":"Maury Y, Come J, Piskorowski RA, et al. Combinatorial analysis of developmental cues efficiently converts human pluripotent stem cells into multiple neuronal subtypes[J]. Nat Biotechnol. 2015;33(1):89\u201396.","journal-title":"Nat Biotechnol"},{"issue":"3","key":"3857_CR141","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1517\/14728214.2015.1041375","volume":"20","author":"B Wirth","year":"2015","unstructured":"Wirth B, Barkats M, Martinat C, et al. Moving towards treatments for spinal muscular atrophy: hopes and limits[J]. Expert Opin Emerg Drugs. 2015;20(3):353\u20136.","journal-title":"Expert Opin Emerg Drugs"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03857-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03857-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03857-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T05:43:55Z","timestamp":1757223835000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03857-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":141,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3857"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03857-3","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]},"assertion":[{"value":"19 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"353"}}